From The Podium - HIVresistanceWeb

Reports from resistance-related conferences and courses
		NEW Antiretroviral Drug Resistance in Non-Subtype B HIV-1 Special guest editor Rami Kantor, M.D., and David Katzenstein, M.D., review the latest data on resistance patterns of non-subtype B viruses from studies around the globe.
		NEW NNRTI Resistance: An Update From the XI International HIV Drug Resistance Workshop Resistance to this class of agents is too well understood, complains Brian Conway, M.D. in his report on all things non-nucleoside.
		NEW New and Current NRTI: An Update From the XI International HIV Drug Resistance Workshop Significant new findings regarding NRTI were presented at the XI International HIV Drug Resistance Workshop. Mark A. Wainberg, Ph.D. reviews breaking resistance data concerning tenofovir and the thymidine analogs, and also new compounds, including MIV-310 (alovudine), boranophosphates, and D-FDOC.
		NEW Update From Barcelona on the Utility of Resistance Testing in Clinical Practice Several new studies presented at the XIV International AIDS Conference in Barcelona addressed the utility and limitations of resistance testing in clinical practice. Here, Michelle E. Roland, M.D. takes a close look at the VIHRES and CERT studies, and at new findings of the Narval study.
		NEW How Do the Experts Do in Interpreting Genotypes? A critical component of HIV drug resistance testing is how well different genotype interpretation methods perform at predicting viral phenotypes and virologic responses to new drug regimens. Michelle E. Roland, M.D. examines new data on the congruity (or lack of it) between expert interpretations and on the concordance (again, or lack of it) of sequence interpretations by one academic and two commercial algorithms.
		NEW Resistance to Protease Inhibitors: An Update From the XI International HIV Drug Resistance Workshop Jonathan M. Schapiro, M.D. updates us from the XI International HIV Drug Resistance Workshop on the next-generation PIs atazanavir and tipranavir and other, new resistance data relevant to PI therapy today.
		Genotyping: It May No Longer be Just for the Virus A growing body of evidence suggests that host genotypic factors – not just viral genotypic factors – are responsible for variability in disease progression, response to ARV therapy, and certain drug-mediated toxic and hypersensitivity effects. Robert Shafer, M.D. reports on the influence of host genomic factors on HIV’s natural history and the metabolism of ARV drugs.
		Non-subtype B HIV and Drug Resistance Can distinct differences in how drug resistance develops be mediated by polymorphisms peculiar to specific HIV subtypes? David Katzenstein, M.D. takes a broad yet deep look at new findings from the 9th CROI on the relationship(s) between HIV subtype and HIV drug resistance.
		Clinically Useful Resistance and Resistance Test Information Michelle Roland, M.D. details evolving information about resistance and resistance testing, including NRTI cross-resistance, assay comparisons, interpretation tools, prospective virologic outcomes studies and phenotypic cut-offs.
		HIV Resistance to Protease Inhibitors A concise review of new data on the investigational PI atazanavir and tipranavir, as well as on lopinavir/r and the veteran PI by Jonathan Schapiro, M.D.
		New Drugs: A Report From the 9th Conference on Retroviruses and Opportunistic Infections Mark A. Wainberg, Ph.D. provides a concise review of preclinical and early clinical data presented at the 9th CROI on new NRTI, NNRTI, integrase inhibitors, co-receptor inhibitors and novel entry inhibitors.
		Primary Resistance: New Data From Around the World New data on the incidence, fitness and transmission of drug-resistant HIV in the US, Europe and Australia. David Katzenstein, M.D. reports on drug resistance among recently infected, ARV-naive patients.
		Resistance Presentations at ICAAC . Lots of news on tenofovir, abacavir, amprenavir, lopinavir/r, fusion inhibitors and assays for the detection of HIV drug resistance. Mark A. Wainberg, Ph.D. provides a comprehensive summary of resistance-related presentations at the 41st ICAAC.
		Updates on NNRTI resistance, the NARVAL study, tenofovir, Kaletra, primary resistance and more . Mark A. Wainberg, Ph.D. provides a comprehensive report on resistance-related data presented at the 1st IAS Conference on HIV Pathogenesis and Treatment in Buenos Aires.
		Interpretive Systems for HIV Drug Resistance Testing: A Report From the 5th International Workshop on HIV Drug Resistance and Treatment Strategies Robert W. Shafer, M.D. takes an in-depth look at systems and methodologies for interpreting HIV drug resistance test results presented at the 5th International Workshop on Drug Resistance.
		NRTI Resistance: A Report From the 5th International Workshop on HIV Drug Resistance and Treatment Strategies Guest author Nancy Shulman, M.D. distills clinically relevant NRTI resistance data presented at the 5th International Workshop on Drug Resistance.
		New Drugs: A Report From the 5th International Workshop on HIV Drug Resistance and Treatment Strategies Mark A. Wainberg, Ph.D. looks at new anti-HIV drugs presented at the 5th International Workshop on Drug Resistance.
		NNRTI Resistance: An Update from the 5th International Workshop on HIV Drug Resistance & Treatment Strategies Brian Conway, M.D. reviews new NNRTI resistance data from all 6 sessions of the 5th International Workshop on Drug Resistance.
		Mechanisms of HIV Drug Resistance: A Report From the 5th International Workshop on HIV Drug Resistance and Treatment Strategies Mark A. Wainberg, Ph.D. reviews data concerning mechanisms of NRTI and PI resistance presented at the 5th International Workshop on Drug Resistance.
		Clinical Information on Resistance Testing: New Clinical Trials and Improvements in Tests and Reports Michelle Roland, MD, reports on clinical and technological issues in HIV drug resistance testing.
		Highlights From the 3rd European Symposium on the Clinical Implications of HIV Drug Resistance Mark Wainberg, Ph.D. takes a look at issues of viral fitness, nucleoside-associated mutations, differences among HIV subtypes, and the predictive value of HIV genotyping, as treated of at the 3rd European Symposium on the Clinical Implications of HIV Drug Resistance.
		Highlights From the 3rd European Symposium on the Clinical Implications of HIV Drug Resistance Charles Boucher, M.D., Ph.D. discusses recent data concerning nucleoside-associated mutations and interpretive systems for genotypic HIV drug resistance assays presented at the 3rd European Symposium on the Clinical Implications of HIV Drug Resistance.
		Primary HIV Drug Resistance HIVresistanceWeb’s primary resistance tracker Douglas Mayers, M.D. reviews the latest resistance data from cohorts of adult seroconverters, adult partner pairs and mother and child pairs.
		Drug Transporters, Sanctuary Sites and HAART Failure What is the role of drug transport molecules in the pharmacology of antiretroviral drugs and the development of HIV drug resistance? Douglas Mayers, M.D. reports on the newest data regarding P-glycoprotein and associated genes.
		Structured Treatment Interruption: Novel Strategy or Oxymoron? What do we know about STI in HIV infection? Brian Conway, M.D. and David Katzenstein, M.D. review the latest findings regarding this strategy in acute and chronic infection.
		Resistance to Nucleoside Analogs: Update From the 8th CROI Charles Boucher, M.D., Ph.D. reports on NRTI resistance data presented at the 8th Conference on Retroviruses and Opportunistic Infections (8th CROI).
		NNRTI Resistance Update: Using the Old Ones, Looking Toward the New Brian Conway, M.D. reports from the 8th CROI on new resistance data concerning available and investigational NNRTIs.
		New Data on Protease Inhibitor Resistance Jonathan M. Schapiro, M.D., reports from the 8th CROI on resistance to Kaletra, amprenavir and other PI.
		Clinical Information on Resistance Testing: New Clinical Trials and Improvements in Tests and Reports—Part One Michelle E. Roland, M.D. reports from the 8^th CROI on the latest prospective and retrospective data from clinical trials of HIV drug resistance testing in antiretroviral-naive and -experienced patients.
		Salvage Therapy: More Data on New Drugs Against Old Targets Robert Shafer, M.D. reports on salvage strategies from the 8^th Conference on Retroviruses and Opportunistic Infections (8^th CROI).
		New Drugs Mark A. Wainberg, Ph.D. reports from the 8^th CROI on the activity of new PIs, nucleosides, NNRTIs and fusion inhibitors against drug-resistant HIV.
		Second Annual Roundtable on HIV Drug Resistance Testing… Convened by HIVresistanceWeb's Board of Advisors, this year’s Roundtable addresses 9 key questions pertaining to the current status, development, and future utility of genotypic and phenotypic drug resistance assays in the clinical management of HIV infection.